Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Non Operating Income (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Non Operating Income data on record, last reported at $25.2 million in Q1 2026.

  • On a quarterly basis, Non Operating Income fell 37.05% to $25.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $142.2 million, a 12.64% increase, with the full-year FY2025 number at $157.0 million, up 48.69% from a year prior.
  • Non Operating Income reached $25.2 million in Q1 2026 per PCVX's latest filing, down from $27.8 million in the prior quarter.
  • Over the last five years, Non Operating Income for PCVX hit a ceiling of $59.6 million in Q2 2025 and a floor of -$646000.0 in Q2 2022.
  • A 5-year average of $21.3 million and a median of $20.4 million in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: plummeted 1366.67% in 2022, then soared 4465.96% in 2023.
  • Tracing PCVX's Non Operating Income over 5 years: stood at $8.5 million in 2022, then soared by 86.26% to $15.9 million in 2023, then soared by 58.04% to $25.1 million in 2024, then grew by 10.71% to $27.8 million in 2025, then dropped by 9.17% to $25.2 million in 2026.
  • Business Quant data shows Non Operating Income for PCVX at $25.2 million in Q1 2026, $27.8 million in Q4 2025, and $29.6 million in Q3 2025.